Current Oncology Reports

, Volume 9, Issue 2, pp 96–101

Cyclooxygenase-2: A novel target in human solid tumors

Authors

    • Department of Human Pathology and OncologyUniversity of Florence, School of Medicine
  • Gian Luigi Taddei
Article

DOI: 10.1007/s11912-007-0004-5

Cite this article as:
Raspollini, M.R. & Taddei, G.L. Curr Oncol Rep (2007) 9: 96. doi:10.1007/s11912-007-0004-5

Abstract

The enzyme cyclooxygenase-2, which is involved in the conversion of arachidonic acid-to-prostanoid synthesis, plays a key role in many inflammatory and proliferative reactions. Experimental data have shown that prostaglandins have a central action in therapeutic targeting not only in the treatment of many inflammatory diseases but also in several types of human cancers. Inhibitors of cyclooxygenase activity seem to protect against carcinoma development and show promise as chemopreventive agents and possible target therapies. Data support new treatments for patients with solid cancers tailored to the molecular characteristics of the individual tumor.

Copyright information

© Current Medicine Group LLC 2007